GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (BUE:AZN) » Definitions » Cyclically Adjusted PB Ratio

AstraZeneca (BUE:AZN) Cyclically Adjusted PB Ratio : 8.11 (As of May. 23, 2024)


View and export this data going back to . Start your Free Trial

What is AstraZeneca Cyclically Adjusted PB Ratio?

As of today (2024-05-23), AstraZeneca's current share price is ARS214.50. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was ARS26.46. AstraZeneca's Cyclically Adjusted PB Ratio for today is 8.11.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PB Ratio or its related term are showing as below:

BUE:AZN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.78   Med: 5.6   Max: 10.1
Current: 9.38

During the past years, AstraZeneca's highest Cyclically Adjusted PB Ratio was 10.10. The lowest was 3.78. And the median was 5.60.

BUE:AZN's Cyclically Adjusted PB Ratio is ranked worse than
93.14% of 685 companies
in the Drug Manufacturers industry
Industry Median: 1.9 vs BUE:AZN: 9.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's adjusted book value per share data for the three months ended in Mar. 2024 was ARS20,350.281. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS26.46 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 7.32 8.24 9.33 8.20

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.16 8.95 8.70 8.20 8.11

Competitive Comparison of AstraZeneca's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.



AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=214.50/26.46
=8.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=20350.281/131.6000*131.6000
=20,350.281

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201406 141.715 99.800 186.871
201409 136.284 100.000 179.350
201412 132.868 99.900 175.029
201503 118.173 99.600 156.140
201506 131.439 100.100 172.801
201509 129.051 100.200 169.492
201512 189.314 100.400 248.145
201603 170.180 100.400 223.065
201606 149.522 101.000 194.823
201609 154.144 101.500 199.856
201612 186.111 102.200 239.650
201703 158.176 102.700 202.687
201706 177.843 103.500 226.127
201709 189.990 104.300 239.719
201712 225.602 105.000 282.755
201803 205.453 105.100 257.256
201806 248.975 105.900 309.397
201809 346.732 106.600 428.048
201812 371.027 107.100 455.902
201903 312.390 107.000 384.211
201906 461.443 107.900 562.798
201909 518.556 108.400 629.538
201912 597.991 108.500 725.305
202003 509.814 108.600 617.786
202006 638.394 108.800 772.175
202009 689.901 109.200 831.419
202012 968.498 109.400 1,165.031
202103 990.184 109.700 1,187.860
202106 1,131.169 111.400 1,336.282
202109 2,508.597 112.400 2,937.112
202112 2,559.491 114.700 2,936.609
202203 2,518.249 116.500 2,844.649
202206 2,790.418 120.500 3,047.461
202209 3,150.589 122.300 3,390.168
202212 4,006.487 125.300 4,207.930
202303 4,561.807 126.800 4,734.494
202306 5,790.177 129.400 5,888.619
202309 8,398.611 130.100 8,495.444
202312 9,115.590 130.500 9,192.426
202403 20,350.281 131.600 20,350.281

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (BUE:AZN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (BUE:AZN) Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (BUE:AZN) Headlines

From GuruFocus